Bright Minds Biosciences Inc(DRUG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DRUG Bright Minds Biosciences Inc

Closed Good Friday 04-17 16:00:00 EDT

33.11

+1.10

+3.44%

盘后33.11

+0.000.00%

18:36 EDT

High33.11	Low31.35	Vol26.02K
Open32.69	D1 Closing32.01	Amplitude5.50%
Mkt Cap233.23M	Tradable Cap83.58M	Total Shares7.04M
T/O849.99K	T/O Rate1.03%	Tradable Shares2.52M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"DRUG","market":"US","secType":"STK","nameCN":"Bright Minds Biosciences Inc","latestPrice":33.11,"timestamp":1744920000000,"preClose":32.01,"halted":0,"volume":26020,"hourTrading":{"tag":"盘后","latestPrice":33.11,"preClose":33.11,"latestTime":"18:36 EDT","volume":87,"amount":2889.82,"timestamp":1744929363049},"delay":0,"floatShares":2524259,"shares":7043989,"eps":-0.151772,"marketStatus":"Closed Good Friday","change":1.1,"latestTime":"04-17 16:00:00 EDT","open":32.69,"high":33.11,"low":31.35,"amount":849988.3146,"amplitude":0.054983,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.151772,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":32.01,"preHourTrading":{"tag":"盘前","latestPrice":32,"preClose":32.01,"latestTime":"08:36 EDT","volume":95,"amount":3036.779975,"timestamp":1744893374218},"postHourTrading":{"tag":"盘后","latestPrice":33.11,"preClose":33.11,"latestTime":"18:36 EDT","volume":87,"amount":2889.82,"timestamp":1744929363049},"volumeRatio":1.198890487581555},"requestUrl":"/m/hq/s/DRUG","defaultTab":"news","newsList":[{"id":"2521172612","title":"Psychedelic: Exclusive talk with biotech company Clearmind Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2521172612","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521172612?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 22:30","pubTimestamp":1742653811,"startTime":"0","endTime":"0","summary":"In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Mark Haden, vice president of business development at Clearmind Medicine , a psychedelic pharmaceutical biotech company focused on development of therapeutics to solve underserved health problems. Here are some highlights:. Discover stocks' market position with detailed  competitor analyses.“Think of this space as being two overlapping circles, a Venn diagram,” Haden said. “There are addiction treatments, like counseling, Alcoholics Anonymous and some pharmaceutical interventions like Antabuse, naltrexone and acamprosate. I ran an addictions treatment program for 28 years and I can assure you that there is relatively low efficacy, the dropout rate is high, and the treatments tend to be very long-term. That’s the first circle.”“You can take MEAI if you are addicted to alcohol and you don’t want to stop,” Haden said. “You can add MEAI to your alcohol and we believe it will result in people drinking less. It c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SEEL","OPTHF","PHRRF","BETRF","QNTM","MYCOF","IXHL","SPRC","BK4547","FLHLF","MDXXF","BK4139","BK4539","ATAI","RLMD","PBM","CMPS","NUMIF","BK4007","MIRA","RVVTF","GHRS","CMND","ALID","AGNPF","SILO","KTTA","ENTBF","DRUG","CYBN","PSYGF","MNMD","SNPX","BK4168","NRXP","BK4202"],"gpt_icon":0},{"id":"2519638156","title":"Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2519638156","media":"TipRanks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519638156?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 23:40","pubTimestamp":1741966809,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a dosing initiation, a development expansion and a distribution agreement.Discover stocks' market position with detailed  competitor analyses.MIRA EXPANDS KETAMIR-2 DEVELOPMENT WITH TOPICAL: On Thursday, MIRA Pharmaceuticals  announced the formulation of Ketamir-2 into a topical treatment for localized neuropathic and inflammatory pain. This expands the company’s pain management portfolio beyond its ongoing Ketamir-2 oral treatment for neuropathic pain, offering a novel, targeted approach for localized pain relief. The topical treatment of Ketamir-2 is designed for slow release, delivering targeted pain relief directly at the application site while minimizing systemic exposure and side effects.“The development of both an oral and topical formulation of Ketamir-2 significantly expands our pipeline and enhances the value proposition of MIRA,” stated Erez Aminov, CEO . “By adv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-atai-reports-dosing-first-154009720.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-atai-reports-dosing-first-154009720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FLHLF","GHRS","DRUG","BK4539","ENTBF","BK4168","PHRRF","SNPX","BK4139","MYCOF","RVVTF","CMPS","BK4202","PSYGF","PBM","QNTM","AGNPF","MDXXF","ALID","OPTHF","BK4547","MNMD","ATAI","CYBN","SEEL","NRXP","SPRC","BETRF","NUMIF","BK4007","SILO","IXHL","RLMD","CMND","ENVB","KTTA","MIRA"],"gpt_icon":0},{"id":"2518471593","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2518471593","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518471593?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 18:00","pubTimestamp":1741687200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Allbirds Inc. Class A                           4Q       4:05 PM. ·Dick's Sporting Gds                              4Q      3.52   7:00 AM. ·E. W. Scripps Co                                 4Q      1.01       AMC. ·European Wax Ctr                                4Q       .06   6:00 AM. ·First Watch Rest                                4Q       .01   7:00 AM. ·Kanzhun Ltd. Sp ADR                               4Q       .22       BMO","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SID","KFY","WSM","BZ","SMSI","AGEN","AKBA","S","EBR","BIRD","KRMD","BW","DKS","LRMR","ONDS","BWAY","KALV","VTS","BTMD","SKIN","SKYX","UNFI","ZYXI","APYX","BLDE","KSS","DRUG","ABM","LEGN","ASRT","ACHV","PHLT","TH","HLLY","AFCG","QRHC","EWCZ","BBCP","WEST","MNTK","FTCI","NOA","MGTX","EXK","SSP","ATLC","SPRB","RMBL","ARCO"],"gpt_icon":1},{"id":"2517859394","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2517859394","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517859394?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 19:00","pubTimestamp":1741345200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Algonquin Pwr & Utl                              4Q       .09       BMO. ·Asana Inc. Class A                              4Q      (.01)  4:05 PM. ·Auna S.A. Class A                               4Q       .15       AMC. ·Vail Resorts Inc.                                2Q      6.29   4:05 PM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACET","AUNA","KALV","EWCZ","EVEX","LEN.B","ORCL","CVGW","BW","CDTX","LE","TBRG","AMRN","BDTX","MOMO","CHRS","BNTX","CING","FERG","DKS","AURA","MGTX","NKTR","BBCP","MYPS","ARCO","ASRT","WEST","DRUG","ADBE","ATLC","FTCI","LRMR","AEO","DRRX","GECC","SSP","CINT","ZVRA","BTMD","NOA","URGN","CIEN","KRMD","HLLY","BWMN","SFIX","LMB","VTS"],"gpt_icon":1},{"id":"2517510851","title":"SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.","url":"https://stock-news.laohu8.com/highlight/detail?id=2517510851","media":"GlobeNewswire","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517510851?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 20:40","pubTimestamp":1741264800,"startTime":"0","endTime":"0","summary":"TAMPA, FL, March  06, 2025  (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced valu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/06/3038102/0/en/SCIENTURE-to-commercially-launch-REZENOPY-a-life-saving-opioid-overdose-emergency-treatment-through-a-collaboration-with-KINDEVA-DRUG-DELIVERY-L-P.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","DRUG","BK4139","SCNX"],"gpt_icon":0},{"id":"2516167545","title":"Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2516167545","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516167545?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 21:00","pubTimestamp":1741093200,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, March 04, 2025  -- Bright Minds Biosciences Inc.   , a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system  disorders, today announced the expansion of its Scientific Advisory Board  to include five distinguished experts in epilepsy research:. Dennis J. Dlugos, MD, MSCE, is Professor of Neurology and Pediatrics at the University of Pennsylvania; and Director, Pediatric Epilepsy Program at Children’s Hospital of Philadelphia . Dr. Dlugos currently serves as a Vice-President of the Epilepsy Study Consortium, Incorporated . As Vice-President, he coordinates reviews and adjudications for pediatric epilepsy trials and participated in discussions with FDA regarding extrapolation of efficacy for focal-onset seizures to one-month to age, and the validity of Developmental and Epileptic Encephalopathy broadly  as a clinical indication for pivotal trials and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bright-minds-biosciences-expands-scientific-130000077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DRUG"],"gpt_icon":0},{"id":"2513470207","title":"Bright Minds Biosciences to Participate at Three Healthcare Conferences in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2513470207","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513470207?lang=en_us&edition=full_marsco","pubTime":"2025-02-24 19:50","pubTimestamp":1740397800,"startTime":"0","endTime":"0","summary":"NEW YORK and VANCOUVER, British Columbia, Feb.  24, 2025  (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on de","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/24/3030985/0/en/Bright-Minds-Biosciences-to-Participate-at-Three-Healthcare-Conferences-in-March.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","CNS","DRUG","BK4137","BK4139","HCSG"],"gpt_icon":0},{"id":"2505979630","title":"Piper Sandler Initiates Bright Minds Biosciences at Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2505979630","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505979630?lang=en_us&edition=full_marsco","pubTime":"2025-01-23 20:44","pubTimestamp":1737636269,"startTime":"0","endTime":"0","summary":"Piper Sandler Initiates Bright Minds Biosciences at Overweight","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DRUG"],"gpt_icon":0},{"id":"2505406018","title":"Yasmeen Rahimi’s Buy Rating on Bright Minds Biosciences Driven by Promising Potential of BMB-101 for Epilepsy Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2505406018","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505406018?lang=en_us&edition=full_marsco","pubTime":"2025-01-23 18:16","pubTimestamp":1737627382,"startTime":"0","endTime":"0","summary":"Bright Minds Biosciences (DRUG) has received a new Buy rating, initiated by Piper Sandler analyst, Yasmeen Rahimi. Yasmeen Rahimi’s rating is based...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/yasmeen-rahimis-buy-rating-on-bright-minds-biosciences-driven-by-promising-potential-of-bmb-101-for-epilepsy-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/yasmeen-rahimis-buy-rating-on-bright-minds-biosciences-driven-by-promising-potential-of-bmb-101-for-epilepsy-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DRUG","BK4139"],"gpt_icon":0},{"id":"2505706019","title":"Bright Minds Biosciences initiated with an Overweight at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2505706019","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505706019?lang=en_us&edition=full_marsco","pubTime":"2025-01-23 18:10","pubTimestamp":1737627022,"startTime":"0","endTime":"0","summary":"Piper Sandler initiated coverage of Bright Minds Biosciences (DRUG) with an Overweight rating and $93 price target The firm believes the company’s ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bright-minds-biosciences-initiated-with-an-overweight-at-piper-sandler?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bright-minds-biosciences-initiated-with-an-overweight-at-piper-sandler?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","DRUG"],"gpt_icon":0},{"id":"2502622861","title":"Cantor Fitzgerald Initiates Bright Minds Biosciences With Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2502622861","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502622861?lang=en_us&edition=full_marsco","pubTime":"2025-01-10 22:03","pubTimestamp":1736517819,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald Initiates Bright Minds Biosciences With Overweight Rating","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DRUG"],"gpt_icon":0},{"id":"2502616798","title":"HC Wainwright Initiates Bright Minds Biosciences With Buy Rating, $85 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2502616798","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502616798?lang=en_us&edition=full_marsco","pubTime":"2025-01-10 22:03","pubTimestamp":1736517797,"startTime":"0","endTime":"0","summary":"HC Wainwright Initiates Bright Minds Biosciences With Buy Rating, $85 Price Target","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DRUG"],"gpt_icon":0},{"id":"2502585628","title":"Bright Minds Biosciences initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2502585628","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502585628?lang=en_us&edition=full_marsco","pubTime":"2025-01-10 19:10","pubTimestamp":1736507438,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio initiated coverage of Bright Minds Biosciences (DRUG) with a Buy rating and $85 price target Bright Minds ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bright-minds-biosciences-initiated-with-a-buy-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bright-minds-biosciences-initiated-with-a-buy-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","DRUG"],"gpt_icon":0},{"id":"2501776272","title":"Press Release: Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2501776272","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501776272?lang=en_us&edition=full_marsco","pubTime":"2025-01-07 19:50","pubTimestamp":1736250600,"startTime":"0","endTime":"0","summary":"Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer. \"As Bright Minds continues to evolve its focus to address conditions with high unmet medical need, including epilepsy, depression, and other central nervous system  disorders, we are thrilled to welcome Dr. Collins at this pivotal time. Throughout his distinguished career as an R&D leader, Steve has a demonstrated track record of leadership and strategic oversight from pre-clinical development through successful commercialization of several drugs across therapeutic areas. His experience advancing novel therapeutics in the CNS space aligns perfectly with our mission to develop the next generation of serotonin drugs to improve patient outcomes,\" said Ian McDonald, CEO and Co-founder of Bright Minds Biosciences.Before heading the two Biscayne companies, Dr. Collins held several top leadership positions at companies targeting CNS disorders, including as CEO of Neurotherapeutics ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMO","BK6027","N32.SI","CNS","BK4139","DRUG","BK4135"],"gpt_icon":0},{"id":"2495611333","title":"Bright Minds Biosciences (DRUG) Finishes the Year with Phenomenal Share Price Increase","url":"https://stock-news.laohu8.com/highlight/detail?id=2495611333","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495611333?lang=en_us&edition=full_marsco","pubTime":"2024-12-31 23:33","pubTimestamp":1735659200,"startTime":"0","endTime":"0","summary":"Bright Minds Biosciences ($DRUG) is finishing 2024 as one of the best-performing small-cap stocks, posting a remarkable 2400% increase in the share...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/bright-minds-biosciences-drug-finishes-the-year-with-phenomenal-share-price-increase?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/bright-minds-biosciences-drug-finishes-the-year-with-phenomenal-share-price-increase?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DRUG","BK4139"],"gpt_icon":0},{"id":"2490724229","title":"CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER","url":"https://stock-news.laohu8.com/highlight/detail?id=2490724229","media":"PR Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490724229?lang=en_us&edition=full_marsco","pubTime":"2024-12-09 20:33","pubTimestamp":1733747580,"startTime":"0","endTime":"0","summary":"WESTON, Fla., Dec. 9, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, announced today that the U.S. Food and Drug Administration  granted Orphan Drug Designation to Cantex's azeliragon for the treatment of brain metastasis from breast cancer. This new azeliragon designation adds to azeliragon's two other Orphan Drug Designations for the treatment of pancreatic cancer and glioblastoma, received in mid-2024 and early 2023, respectively.\"Receiving FDA Orphan Drug Designation for azeliragon for the treatment of brain metastasis from breast cancer highlights a continued need for new treatment options for these patients,\" commented Stephen G. Marcus, M.D., Chief Executive Officer of Cantex. \"This designation reflects our continued commitment to developing new azeliragon treatment options for patients with life-threatening cancer.\". In addition to","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/HXT9jUN9ExWzYJDu4JZHww--~B/aD0xNjE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/da286c53b030ba519a74b40ffe373e9c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/HXT9jUN9ExWzYJDu4JZHww--~B/aD0xNjE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/da286c53b030ba519a74b40ffe373e9c"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cantex-pharmaceuticals-receives-fda-orphan-123300855.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cantex-pharmaceuticals-receives-fda-orphan-123300855.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4024","FOR","VTVT","DRUG","BK4139"],"gpt_icon":0},{"id":"2486072745","title":"Baird Initiates Bright Minds Biosciences at Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2486072745","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486072745?lang=en_us&edition=full_marsco","pubTime":"2024-11-26 20:59","pubTimestamp":1732625951,"startTime":"0","endTime":"0","summary":"Bright Minds Biosciences (DRUG)(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DRUG"],"gpt_icon":0},{"id":"2486049918","title":"Bright Minds Biosciences Inc : Baird Initiates Coverage With Outperform Rating and $75 Target Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2486049918","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486049918?lang=en_us&edition=full_marsco","pubTime":"2024-11-26 15:06","pubTimestamp":1732604811,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241126:nFWN3MW12D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DRUG"],"gpt_icon":0},{"id":"2486061931","title":"Bright Minds Biosciences: Promising Pipeline and Strategic Positioning Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2486061931","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486061931?lang=en_us&edition=full_marsco","pubTime":"2024-11-26 06:25","pubTimestamp":1732573511,"startTime":"0","endTime":"0","summary":"Joel Beatty, an analyst from Robert W. Baird, has initiated a new Buy rating on Bright Minds Biosciences (DRUG). Joel Beatty has given his Buy rati...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bright-minds-biosciences-promising-pipeline-and-strategic-positioning-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bright-minds-biosciences-promising-pipeline-and-strategic-positioning-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XELB","DRUG","BK4094","BK4139"],"gpt_icon":0},{"id":"2486406810","title":"Bright Minds Biosciences initiated with an Outperform at Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2486406810","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486406810?lang=en_us&edition=full_marsco","pubTime":"2024-11-26 05:15","pubTimestamp":1732569358,"startTime":"0","endTime":"0","summary":"Baird initiated coverage of Bright Minds Biosciences (DRUG) with an Outperform rating and $75 price target. Lead agent BMB-101 is entering Phase 2 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bright-minds-biosciences-initiated-with-an-outperform-at-baird?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bright-minds-biosciences-initiated-with-an-outperform-at-baird?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DRUG","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.brightmindsbio.com","stockEarnings":[{"period":"1week","weight":0.1513},{"period":"1month","weight":-0.0718},{"period":"3month","weight":-0.0998},{"period":"6month","weight":-0.2987},{"period":"1year","weight":28.0439},{"period":"ytd","weight":-0.0808}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":0.048249},{"month":2,"riseRate":0.25,"avgChangeRate":-0.102538},{"month":3,"riseRate":0,"avgChangeRate":-0.218801},{"month":4,"riseRate":0.25,"avgChangeRate":-0.058246},{"month":5,"riseRate":0.666667,"avgChangeRate":0.142657},{"month":6,"riseRate":0,"avgChangeRate":-0.154404},{"month":7,"riseRate":1,"avgChangeRate":0.255985},{"month":8,"riseRate":0.333333,"avgChangeRate":0.120025},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.170472},{"month":10,"riseRate":0.333333,"avgChangeRate":12.882876},{"month":11,"riseRate":0.333333,"avgChangeRate":0.011258},{"month":12,"riseRate":0.25,"avgChangeRate":-0.168777}],"exchange":"NASDAQ","name":"Bright Minds Biosciences Inc","nameEN":"Bright Minds Biosciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Bright Minds Biosciences Inc(DRUG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Bright Minds Biosciences Inc(DRUG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Bright Minds Biosciences Inc,DRUG,Bright Minds Biosciences Inc股票,Bright Minds Biosciences Inc股票老虎,Bright Minds Biosciences Inc股票老虎国际,Bright Minds Biosciences Inc行情,Bright Minds Biosciences Inc股票行情,Bright Minds Biosciences Inc股价,Bright Minds Biosciences Inc股市,Bright Minds Biosciences Inc股票价格,Bright Minds Biosciences Inc股票交易,Bright Minds Biosciences Inc股票购买,Bright Minds Biosciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Bright Minds Biosciences Inc(DRUG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Bright Minds Biosciences Inc(DRUG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction